Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q14318
UPID:
FKBP8_HUMAN
Alternative names:
38 kDa FK506-binding protein; FK506-binding protein 8; FKBPR38; Rotamase
Alternative UPACC:
Q14318; C8C9T5; Q53GU3; Q7Z349; Q86YK6
Background:
Peptidyl-prolyl cis-trans isomerase FKBP8, also known as FK506-binding protein 8 or FKBPR38, plays a pivotal role in cellular processes. This protein, characterized by its inactivity that is reversed in the presence of calmodulin and calcium, functions as a chaperone for BCL2, directing it to mitochondria and influencing its phosphorylation state. The interaction between BCL2, FKBP8, calmodulin, and calcium is crucial for modulating BCL2's target binding, implicating FKBP8 in apoptosis regulation. Additionally, FKBP8 has been identified as a key player in inhibiting viral infection by influenza A viruses, highlighting its importance in immune response.
Therapeutic significance:
Understanding the role of Peptidyl-prolyl cis-trans isomerase FKBP8 could open doors to potential therapeutic strategies.